Presentations and Publications

Reneo Pharmaceuticals Research

An open-label study to evaluate the safety and tolerability of 12 weeks of treatment with oral REN001 in subjects with long-chain fatty acid oxidation disorders (LC-FAOD)

Vockley et al., INFORM 2022

Click to view

A prospective, multicenter, non-interventional study to investigate the disease characteristics of adult patients with long-chain fatty acid oxidation disorders: The FORWARD study

Gillingham et al., INFORM 2022

Click to view

A Phase 1 Randomized, Placebo-Controlled, Parallel Study of the Novel Peroxisome Proliferator-Activated Receptor δ Agonist REN001 in Healthy Volunteers during and After Limb Immobilization

Davies et al., Journal of Clinical Trials 2022

Click to view

Treatment with REN001, a Novel PPARδ Agonist, Preserves Muscle Strength and Promotes Recovery of Muscle Atrophy After Prolonged Leg Immobilization

Davies et al., International Congress on Neuromuscular Diseases, 2022

Click to view

REN001, a novel peroxisome proliferator-activated receptor delta (PPARδ)agonist, improves gait in patients with primary mitochondrial myopathy after 12-weeks

Alcock et al., Neuromuscular Medicine, 2022

Click to view